Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-1959D Vaccine in Early Alzheimer's Disease
NCT05642429Phase 1Completed
- Sponsor
- Institute for Molecular Medicine
- Start
- Feb 2023
- Primary completion
- Aug 2025
- Modality
- Split/Subunit Vaccines, DNA Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AV-1959D in Alzheimer's disease (AD) (4 arms), sponsored by Institute for Molecular Medicine. Primary endpoint: Treatment-Emergent Adverse Events or Serious Adverse Events at 28 weeks. Started Feb 2023; status: completed.
02
Drugs
AV-1959D
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05642429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642429.